- Newly public Shuttle Pharmaceuticals ( NASDAQ: SHPH ) on Thursday said it had been awarded patents in the U.S. and Hong Kong for its technology platform which reduces side effects for cancer patients treated with radiation therapy.
- The awarded patents were for SHPH's radiation sensitizing HDAC inhibitor technology platform, the company said in a statement .
- Histone deacetylase (HDAC) inhibitors are a class of drugs that target enzymes involved in the regulation of cellular functions that can inhibit cancer growth.
- The patents awarded were U.S. patent no. 11,407,723 and Hong Kong patent no. HK1250474, SHPH said, with European applications also under review.
- Shares of Shuttle Pharmaceuticals ( SHPH ) were 44.8% lower at $20.68 in mid-day trading, continuing their wild post-IPO ride.
- SHPH went public on Aug. 31, where it soared more than 300% , and has posted extreme swings in both negative and positive territories since then.
For further details see:
Shuttle Pharma awarded new patents for its radiation sensitizing technology platform